Granules India reported its highest-ever quarterly revenue of Rs 15,600 crore, marking a 20% YoY increase. While net profit surged 39%, investors are monitoring 11 U.S. FDA observations at the Gagillapur plant, which management maintains do not impact current operations.
Granules India Q2 Profit Surges 39% Despite Regulatory Oversight
Revenue reached Rs 15,600 million (+20% YoY); Net Profit stood at Rs 1,818 million (+39% YoY).
Reader Takeaway: Strong operational growth and net cash position boost confidence, despite ongoing U.S. FDA review of Gagillapur facility.
What just happened
Granules India delivered a robust performance for the second quarter of FY27. The company hit a milestone, recording its highest-ever quarterly revenue of Rs 15,600 million. Profitability grew even faster, with net profit after tax rising 39% to Rs 1,818 million. A notable balance sheet shift occurred, as the company moved from a net debt of Rs 1,012 million in Q1 to a net cash position of Rs 8,280 million, bolstered by warrant proceeds.
Regulatory Update: Gagillapur Facility
The company disclosed 11 observations issued by the U.S. FDA following an inspection of its Gagillapur facility in October 2026. Management clarified that these observations—which relate to process documentation and control systems—do not involve data integrity or cross-contamination issues. Production and distribution remain unaffected, and the firm is preparing a formal response with corrective and preventive actions (CAPA) to be filed within 15 business days.
Strategy and Capex
Granules India announced a significant capital expenditure program of Rs 2,000 crore scheduled over the next 3-4 years. Funds will be directed toward expanding the peptide CDMO vertical in Zurich and India, upgrading U.S. distribution capabilities, and increasing API production capacity for oncology products.
Risks to watch
Despite strong top-line growth, gross margins dipped 134 basis points to 64.4%. Management cited higher input costs and logistics pressures stemming from geopolitical tensions in West Asia. The ability to pass these costs onto customers will remain a key factor for margin stability in upcoming quarters.
What to track next
The company has planned five new product launches in the U.S. market for the second half of the year. Additionally, the progress of the peptide CDMO business (Senn Tides) remains a focal point, particularly after the unit successfully cleared a Swiss Medic inspection.